Life
BioNTech Founders Transition to New mRNA-Focused Venture
Ugur Sahin and Özlem Türeci, co-founders of BioNTech, are departing to establish a new company centered on mRNA technology, signaling a shift in their strategic focus.
Editorial Staff
1 min read
Ugur Sahin and Özlem Türeci, the innovative duo behind BioNTech, are set to leave the company to launch a new venture dedicated to mRNA technology.
This transition may influence the current landscape of mRNA applications, particularly in vaccine development and therapeutic solutions.
The founders' expertise in mRNA could enhance the capabilities and efficiencies of their new firm, potentially impacting future market dynamics.